trending Market Intelligence /marketintelligence/en/news-insights/trending/L18j5gJQ4cAbU_Jd_1ui8w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Kyowa Kirin's add-on therapy for Parkinson's disease accepted for EU review

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Kyowa Kirin's add-on therapy for Parkinson's disease accepted for EU review

The European Medicines Agency accepted Kyowa Kirin Co. Ltd.'s Parkinson's treatment istradefylline, or KW-6002, for review.

The Tokyo-based pharmaceutical company is seeking the EMA's approval to use istradefylline, which is known as Nourianz in the U.S., as an additional treatment for Parkinson's patients who are experiencing so-called off periods. These periods occur in patients taking levodopa or levodopa-based regimens, but either do not see any benefit or experience a delay before the medication takes effect.

During off times, Parkinson's symptoms re-emerge and can reach, or are, at their worst. According to an estimate, more than 40% of Parkinson's patients experience off episodes after taking levodopa for four to six years.

Levodopa is one of the main drugs used to treat Parkinson's.

Kyowa Kirin said its application was supported by clinical trials that evaluated the medicine's effectiveness in patients taking levodopa-based treatment regimens, regardless of whether they were taking any additional medications for their condition.